Rhythm Pharmaceuticals, Inc. — Earnings Quality Grade F
RYTM · Healthcare
Major red flags
Screening Summary
管理层信号
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 50 days, change -2 days YoY
AR growth 40.9% vs revenue growth 45.8%
Revenue grew 45.8% but CFFO declined -1.6%
Expense Quality
Inventory 37.4% vs COGS 45.8%. Normal
Insufficient data
SG&A/Gross Profit = 114.5%, exceeds 70%
Gross margin 89.7%, change +0.0pp. Stable
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
FCF is negative ($-0.1B)
Accruals ratio = -16.8%. Low accruals
Cash $0.4B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Interest coverage = -9.3x (<2x). Financial stress
Other assets -51.1% vs revenue 45.8%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 2/3 years
No goodwill
Manipulation Score
M-Score = -2.97 (< -2.22). Unlikely manipulator
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25